SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-024932
Filing Date
2021-05-06
Accepted
2021-05-06 16:02:19
Documents
61
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q Q1 2021 spro-10q_20210331.htm   iXBRL 10-Q 2658850
2 EX-31.1 spro-ex311_8.htm EX-31.1 8992
3 EX-31.2 spro-ex312_9.htm EX-31.2 9075
4 EX-32 spro-ex32_131.htm EX-32 6617
  Complete submission text file 0001564590-21-024932.txt   8523529

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA spro-20210331.xsd EX-101.SCH 63178
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE spro-20210331_cal.xml EX-101.CAL 41281
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE spro-20210331_def.xml EX-101.DEF 208918
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20210331_lab.xml EX-101.LAB 460857
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20210331_pre.xml EX-101.PRE 345776
10 EXTRACTED XBRL INSTANCE DOCUMENT spro-10q_20210331_htm.xml XML 1415595
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 21897597
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences